Patents by Inventor Atsuo Yonezawa
Atsuo Yonezawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10927185Abstract: [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process.Type: GrantFiled: November 20, 2015Date of Patent: February 23, 2021Assignee: Astellas Pharma Inc.Inventors: Yasuhiro Ito, Atsuo Yonezawa
-
Publication number: 20170306053Abstract: [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process.Type: ApplicationFiled: November 20, 2015Publication date: October 26, 2017Applicant: Astellas Pharma Inc.Inventors: Yasuhiro ITO, Atsuo YONEZAWA
-
Patent number: 9371391Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.Type: GrantFiled: February 27, 2013Date of Patent: June 21, 2016Assignee: Astellas Pharma Inc.Inventors: Atsuo Yonezawa, Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
-
Patent number: 9127055Abstract: Anti-human NGF antibodies are useful for treating pain.Type: GrantFiled: February 8, 2013Date of Patent: September 8, 2015Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20150218265Abstract: To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: ApplicationFiled: January 14, 2015Publication date: August 6, 2015Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20150126713Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases such as ophthalmic disease, inflammatory bowel disease, or psoriasis in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:10 or 14 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:6 or 18.Type: ApplicationFiled: February 27, 2013Publication date: May 7, 2015Applicant: Astellas Pharma Inc.Inventors: Atsuo Yonezawa, Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
-
Patent number: 8986952Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: GrantFiled: August 10, 2012Date of Patent: March 24, 2015Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140227287Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as the effects on a fetus, thrombus formation, and joint-related adverse events such as RPOA while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:4.Type: ApplicationFiled: February 8, 2013Publication date: August 14, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi KAMOHARA, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140155582Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: ApplicationFiled: August 10, 2012Publication date: June 5, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi